Comparing Substance Use Consequences between Serotonergic Psychedelics, MDMA, and other Drugs of Abuse Among United States Adults with History of Psychiatric Illness.

Psychedelic-assisted therapy could transform treating psychiatric illness, but harms from exacerbating substance use disorder (SUD) among adults with psychiatric illness using psychedelics have not been studied. A cross-sectional survey in the US was used to test whether Drug Abuse Screening Test sc...

Descripción completa

Detalles Bibliográficos
Publicado en:International Journal of Mental Health & Addiction Vol. 23; no. 2; pp. 1179 - 1193
Autores principales: Black, Joshua C., Schow, Nicole, Burkett, Hannah L., Pena, Morgan, Jewell, Jennifer S., Czizik, Annika, Monte, Andrew A., Dart, Richard C.
Formato: Artículo
Publicado: Springer Nature Apr2025
Materias:
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=184826067&site=ehost-live
header:
  @attributes:
    shortDbName: ssf
    uiTerm: 184826067
    longDbName: Social Sciences Full Text (H.W. Wilson)
    uiTag: AN
  controlInfo:
    bkinfo:
    jinfo:
      jid:
        15571874
        46AW
      jtl: International Journal of Mental Health & Addiction
      issn: 15571874
      maglogo: N
    pubinfo:
      dt: Apr2025
      vid: 23
      iid: 2
      pid: 237
      pub: Springer Nature
    artinfo:
      ui:
        184826067
        10.1007/s11469-023-01163-2
      ppf: 1179
      ppct: 14
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
              size: 1.3MB
      tig:
        atl: Comparing Substance Use Consequences between Serotonergic Psychedelics, MDMA, and other Drugs of Abuse Among United States Adults with History of Psychiatric Illness.
      aug:
        au:
          Black, Joshua C.
          Schow, Nicole
          Burkett, Hannah L.
          Pena, Morgan
          Jewell, Jennifer S.
          Czizik, Annika
          Monte, Andrew A.
          Dart, Richard C.
        affil:
          https://ror.org/01fbz6h17 Rocky Mountain Poison & Drug Safety, Denver Health and Hospital Authority, 1391 N. Speer Blvd, #600, M/C 0180, 80204, Denver, CO, USA
          https://ror.org/04cqn7d42 Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
      su:
        Mental depression
        Medical sciences
        Bipolar disorder
        Post-traumatic stress disorder
        United States history
        Psilocybin
      sug:
        subj:
          Mental depression
          Medical sciences
          Bipolar disorder
          Post-traumatic stress disorder
          United States history
          Psilocybin
      keyword:
        LSD
        MDMA
        Medical and Health Sciences Clinical Sciences
        Psychedelics
        Psychiatric illness
        US population
        LSD
        MDMA
        Medical and Health Sciences Clinical Sciences
        Psychedelics
        Psychiatric illness
        US population
      ab: Psychedelic-assisted therapy could transform treating psychiatric illness, but harms from exacerbating substance use disorder (SUD) among adults with psychiatric illness using psychedelics have not been studied. A cross-sectional survey in the US was used to test whether Drug Abuse Screening Test scores (DAST-10, validated instrument predicting SUD) were more severe when psychiatric illnesses (anxiety disorder, major depressive disorder [MDD], post-traumatic stress disorder [PTSD], and bipolar disorder) and serotonergic psychedelic or MDMA use were combined. Any psychedelic use among adults with psychiatric illness history (anxiety: 5.1% [95% CI: 4.7, 5.6]; MDD: 5.1% [4.3, 5.8]; PTSD: 6.9% [5.9, 7.9]; bipolar: 9.2% [8.0, 10.5]) was more prevalent than the general population (2.6% [2.5, 2.8]). Significant increases in scores were associated with psychedelic use independent of other concurrent drug use, but increases were smaller than for opioids or stimulants. Approaches to managing SUD risks with psychedelics should differ from past approaches for other drugs.
      pubtype: Academic Journal
      doctype: Article
      src: R
    language: English
    refInfo:
    copyright:
      @attributes:
        flag: N
    holdings:
      @attributes:
        islocal: N